Skip to content

2018 Next Milestone Ventures

Stephen Chang

Atmosphere==
NYSCF Annual Summer Cocktail Reception==
Private Residence, Sagaponack, NY==
July 15, 2016==
©Patrick McMullan==
Photo - Sean Zanni/PMC==
==

Firm

Histogen, Inc.

Human geneticist with 30 plus years of commercial experience in life sciences in areas of stem cells, cell and gene therapy and drug development. Entrepreneur, teacher and scientific and business leader in life science with specific emphasis on small company startups. I provide leadership, strategy, startup counseling and drug development of complex drug products. A recognized pioneer in commercial gene therapy and complex biologicals.

PROFESSIONAL EXPERIENCE
Independent Consultant (Present)
Providing strategic contacts, programs and training to small foundations, banks and companies in the area of life science technology in area of life science tools, technologies and therapeutics. Also in the process of founding companies in area of life science with other founders and consultants. Orphesus Therapeutics (San Francisco, iNKT small molecule cancer), Legacy Therapeutics( San Diego, non viral gene therapy), Promethesus Therapeutics (inflammation and neurological disease) and Princeton Drug Discovery (small molecule cancer drugs in validated targets). On Board of Orpheus Therapeutics and Histogen, Inc. Also serving as entrepreneur in residence at Rutgers and NYU. Also strategic advisor to CEO of Mirimus a tools company for Downstate New York.

Chairman and Acting CEO of Histogen, Inc (Present)
Providing strategic direction, financing strategy and operational experience to a struggling San Diego biotech company in the area of cosmetic and regenerative hair growth. Begun strategic divestiture of assets to partners. Allergan deal accomplished on 7/24/17 for cosmetic product line with royalties, manufacturing and technology transfer. Raised $11 million in non dilutive financing. Exploring sale/partnering of company with large pharmaceuticals in area of hair growth and skin care. Recently filed an IND for Alopecia which was accepted by FDA to proceed to clinical trials on May 3, 2018. Involved in strategic negotiations of licensing, business development and operations of Histogen on a weekly basis. Phase 1 studies are now ongoing.

Newsletter Signup

Next Milestone is a Program of